Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates Strategic Highlights Received an issued US Patent titled “High Throughput Optical Assay of Human Mixed Cell Population Spheroids” by the United States...

Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein Therapeutics New collaboration mitigates risk in drug discovery process with artificial intelligence and in vitro “avatar” clinical trials CHERRY HILL, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc....

Cellaria Adds Next-Generation RNA Reprogramming and Stem Cell Services CAMBRIDGE, Mass., March 20, 2017 (GLOBE NEWSWIRE) -- Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging tumors, today announced the expansion of its...

Cellaria Forms Strategic Partnership with AMS Biotechnology CAMBRIDGE, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific cancer models for challenging tumors, today announced the...

Cellaria to Release Novel Ovarian and Breast Cancer Cell Models CAMBRIDGE, Mass., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging tumors, today announced the release of two new...